Halozyme Therapeutics HALO Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's operating lease ROU assets?
- Halozyme Therapeutics (HALO) reported operating lease ROU assets of $30.85M in Q3 2025.
- How has Halozyme Therapeutics's operating lease ROU assets changed year-over-year?
- Halozyme Therapeutics's operating lease ROU assets decreased by 10.6% year-over-year, from $34.51M to $30.85M.
- What is the long-term trend for Halozyme Therapeutics's operating lease ROU assets?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's operating lease ROU assets has grown at a 79.4% compound annual growth rate (CAGR), from $3.3M to $34.17M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.